Skip to main content
SpringerLink
Log in

Morphological Detection of Hormone and Growth Factor Receptors in Breast Cancer

  • Chapter
Targeted Therapies in Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 176))

  • 1163 Accesses

Abstract

In the multidisciplinary effort of today’s clinical oncology, histopathology has to deal increasingly with the genetic and proteomic profiles of neoplastic cells obtained in ever smaller samples via various diagnostic routes. None of the numerous molecular markers available has surpassed hormone and growth factor receptors in their relevance for the selection of targeted therapies. In the following, morphologic concepts and histopathologic methods pertinent to the clinically most important receptors are discussed with a focus on tumors of the breast.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Allred D, Bryant J, Land S, Paik S, Fisher E, Julian T, Fisher B (2002) Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP protocol B-24. Breast Cancer Res Treat 78:36

    Google Scholar 

  • Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261

    Article  PubMed  CAS  Google Scholar 

  • Bartlett JMS, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG (2001) Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 195:422–428

    Article  PubMed  CAS  Google Scholar 

  • Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973–1979

    Article  PubMed  CAS  Google Scholar 

  • Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR (2001) 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865–1878

    PubMed  Google Scholar 

  • Beck T, Weikel W, Brumm C, Wilkens C, Pollow K, Knapstein PG (1994) Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). Gynecol Oncol 53:220–227

    Article  PubMed  CAS  Google Scholar 

  • Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G, van de Vijver M (2003) Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 16:173–182

    Article  PubMed  Google Scholar 

  • Bofin AM, Ytterhus B, Martin C, O’Leary JJ, Hagmar BM (2004) Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 122:110–119

    Article  PubMed  CAS  Google Scholar 

  • Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748–3757

    PubMed  CAS  Google Scholar 

  • Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R (2004) The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 100:2317–2327

    Article  PubMed  Google Scholar 

  • Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816

    PubMed  CAS  Google Scholar 

  • Ferno M, Stal O, Baldetorp B, Hatschek T, Kallstrom AC, Malmstrom P, Nordenskjold B, Ryden S (2000) Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels: South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 59:69–76

    Article  PubMed  CAS  Google Scholar 

  • Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583

    Article  PubMed  CAS  Google Scholar 

  • Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F (2003) Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86–92

    Article  PubMed  Google Scholar 

  • Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481

    PubMed  CAS  Google Scholar 

  • Herynk MH, Fuqua SA (2004) Estrogen receptor mutations in human disease. Endocr Rev 25:869–898

    Article  PubMed  CAS  Google Scholar 

  • Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H (2002) Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. Am J Clin Pathol 118:693–698

    Article  PubMed  CAS  Google Scholar 

  • Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR (2005) Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 58:611–616

    Article  PubMed  CAS  Google Scholar 

  • Iwao K, Miyoshi Y, Egawa C, Ikeda N, Tsukamoto F, Noguchi S (2000) Quantitative analysis of estrogen receptor-alpha and-beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Cancer 89:1732–1738

    Article  PubMed  CAS  Google Scholar 

  • Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A 98:15197–15202

    Article  PubMed  CAS  Google Scholar 

  • Mosselman S, Polman J, Dijkema R (1996) ER-beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49–53

    Article  PubMed  CAS  Google Scholar 

  • Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596–2606

    PubMed  CAS  Google Scholar 

  • Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, Keramopoulos A (2004) The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57:523–528

    Article  PubMed  CAS  Google Scholar 

  • Perin T, Canzonieri V, Massarut S, Bidoli E, Rossi C, Roncadin M, Carbone A (1996) Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur J Cancer 32A:1148–1155

    Article  PubMed  CAS  Google Scholar 

  • Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20:3095–3105

    PubMed  CAS  Google Scholar 

  • Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598–6607

    Article  PubMed  CAS  Google Scholar 

  • Regan MM, Viale G, Mastropasqua MG, et al (2006) Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98:1571–1581

    Article  PubMed  CAS  Google Scholar 

  • Rhodes A (2003) Quality assurance in immunohistochemistry. Am J Surg Pathol 27:1284–1285

    PubMed  Google Scholar 

  • Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD (2000) Reliability of immunohistochemical demonstration of estrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 53:125–130

    Article  PubMed  CAS  Google Scholar 

  • Rhodes A, Jasani B, Balaton AJ, Barnes DM, Anderson E, Bobrow LG, Miller KD (2001) Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe: documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 115:44–58

    Article  PubMed  CAS  Google Scholar 

  • Roka S, Rudas M, Taucher S, Dubsky P, Bachleitner-Hofmann T, Kandioler D, Gnant M, Jakesz R (2004) High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol 30:243–247

    Article  PubMed  CAS  Google Scholar 

  • Rossi S, Laurino L, Furlanetto A, Chinellato S, Orvieto E, Canal F, Facchetti F, Dei Tos AP (2005) Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol 124:295–302

    Article  PubMed  CAS  Google Scholar 

  • Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V (2002) Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 197:155–162

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  • Spieker-Polet H, Sethupathi P, Yam PC, Knight KL (1995) Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc Natl Acad Sci U S A 92:9348–9352

    Article  PubMed  CAS  Google Scholar 

  • Spiers V, Parkes A, Kerin MJ, Walton DS, Carleton PJ, Fox JN, Atkin SA (1999) Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Res 59:525–528

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centrum 5 für diagnostische und präventive Labormedizin, Institut für Pathologie, Charité Campus Mitte, 13344, Berlin, Germany

    Konrad Kölble MD, PhD (Charité)

Authors
  1. Konrad Kölble MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Pathologie, Charité Humboldt-Universität zu Berlin, Schumanstr. 20-21, 10117, Berlin, Germany

    Manfred Dietel

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kölble, K. (2007). Morphological Detection of Hormone and Growth Factor Receptors in Breast Cancer. In: Dietel, M. (eds) Targeted Therapies in Cancer. Recent Results in Cancer Research, vol 176. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-46091-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-46091-6_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-46090-9

  • Online ISBN: 978-3-540-46091-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation